EU PERSPECTIVES - A cancer treatment can clear Europe-wide approval, yet patient access still varies enormously from one country to the next. The difference is as much as three years, Isabel Rubio, the president of the European Cancer Organisation tells EU Perspectives. Read more

EU PERSPECTIVES - For the second year running, member states have refused to sign off the EU4Health budget 2026, over cuts to core funding for health NGOs. EUPHA (European Public Health Association) president Tit Albreht spoke to EU Perspectives about why public health cannot turn to industry money, and what Europe loses if it lets health funding...

EU PERSPECTIVES - Artificial intelligence (AI) is scanning breasts in Turkey, reading X-rays in Portugal and phoning elderly patients at home. The technology has arrived. The rules to govern it are being drafted elsewhere, and health is not at the table. Read more

EU PERSPECTIVES - Some pharmaceutical companies are openly warning that they could delay bringing their medicines to Europe. Solène Jouan is not willing to accept it. The policy officer at the European Patients' Forum believes such warnings place undue pressure on member states and already overstretched health systems. Ultimately, she argues, the...

EURACTIV - With global attention turning to expanding HIV prevention, Médecins Sans Frontières (MSF) is urging governments worldwide to ensure the twice-yearly drug lenacapavir becomes affordable and widely accessible. Its Belgian section made the appeal from Brussels during the 26th International AIDS Conference in Rio de Janeiro, calling on the...

EU PERSPECTIVES - Europe has learned to count the people extreme heat kills. It has barely begun to count what that heat does to the minds of those who live through it. Read more

EU PERSPECTIVES - Screens are not the main culprit behind Europe's youth mental health crisis. They merely amplify problems that already exist, and ignoring the crisis now could cost the EU €1.68tn over the next decade. Read more

EU PERSPECTIVES - The EU has agreed its landmark law against drug shortages. The regulator who has to deliver it just put a number on the work ahead. Read more

EURACTIV - Austria provisionally reimburses the new anti-amyloid Alzheimer's therapies, disease-modifying antibodies such as lecanemab and donanemab – and runs treatment centres in every province. On paper, it is a model rollout. Read more

EURACTIV - For the first time, medicine can slow Alzheimer's disease, but the new drugs only work early, and across Europe most people are still diagnosed too late or not at all. Mercè Boada Rovira, one of Spain's most experienced dementia clinicians, told a policy meeting in Rome what it would take to change that. Read more